EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of Atrasentan Metabolic Pathway in Human Liver Microsomes Using Feature-Based Molecular Networking

Hyung-Ju Seo iD, Zhuoning Liang iD, Eui-Hyeon Kim iD, Kwang-Hyeon Liu iD

Pharmaceutics · 13.06.2026 · 18 (6) · 731

DOI: 10.3390/pharmaceutics18060731 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 13.06.2026. Verfasst von Hyung-Ju Seo und 3 weiteren Autor:innen. Beteiligte Einrichtung: BK21 FOUR KNU Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy, Research Institute of Pharmaceutical Sciences, Ky…. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Education, National Research Facilities and Equipment Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Atrasentan is a selective endothelin A receptor antagonist (SERA) developed as a potential therapy for chronic renal diseases, including diabetic nephropathy and immunoglobulin A nephropathy. Despite this potential, understanding its metabolic bioactivation is essential for assessing the risks of drug-induced liver injury (DILI). However, the metabolic profile of atrasentan remains poorly characterized, and the mechanisms underlying its potential hepatotoxicity remain underexplored. Therefore, this study aims to investigate the metabolic pathways of atrasentan in human liver microsomes (HLMs) in the presence of nicotinamide adenine dinucleotide phosphate (NADP+), uridine diphosphate glucuronic acid (UDPGA), or glutathione (GSH).

Methods

A liquid chromatography–high resolution mass spectrometry (LC-HRMS) coupled with a feature-based molecular networking approach was used to characterize metabolites. Characterization of the major metabolites was achieved through cytochrome P450 (P450) phenotyping with human recombinant P450 isoforms.

Results

A total of eighteen metabolites were characterized through phase I and II metabolic reactions, including demethylenation, N-dealkylation, O-demethylation, hydroxylation, dehydrogenation, and glucuronidation. Atrasentan acyl glucuronide (M8) was confirmed as the predominant metabolite, and we also putatively annotated a catechol intermediate (M5) and its corresponding GSH conjugate (M15). Characterizing the GSH conjugate (M15) indicates that catechol intermediate (M5) can be further oxidized to a reactive ortho-quinone intermediate, which is subsequently trapped by GSH, suggesting the potential for a bioactivation mechanism. Reaction phenotyping demonstrated that the formation of M5 is catalyzed almost exclusively by the CYP3A subfamily. However, its direct translation to in vivo oxidative stress or covalent protein binding requires further studies.

Conclusions

These findings demonstrate that feature-based molecular networking is a valuable strategy for metabolite characterization, underscoring the urgent need for further in vivo metabolism studies to definitively assess hepatotoxic risks associated with these reactive metabolites.

Schlagwörter

Stichwörter der Autor:innen

atrasentancharacterizationdrug-induced liver injuryfeature-based molecular networkingmetabolismreactive metabolite

Autor:innen und Institutionen

  • BK21 FOUR KNU Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Republic of Korea.
  • Clinical Omics Institute, School of Medicine, Kyungpook National University, Daegu 41405, Republic of Korea.
  • Mass Spectrometry Based Convergence Research Institute, Kyungpook National University, Daegu 41566, Republic of Korea.

ORCID-Profile: Hyung-Ju Seo, Zhuoning Liang, Eui-Hyeon Kim, Kwang-Hyeon Liu

Förderung

  • National Research Foundation of Korea
  • Ministry of Education
  • National Research Facilities and Equipment Center

Zitieren

APA

Seo, H. J., Liang, Z., Kim, E. H., & Liu, K. H. (2026). Characterization of Atrasentan Metabolic Pathway in Human Liver Microsomes Using Feature-Based Molecular Networking. Pharmaceutics, 18(6), 731. https://doi.org/10.3390/pharmaceutics18060731

Vancouver

Seo HJ, Liang Z, Kim EH, Liu KH. Characterization of Atrasentan Metabolic Pathway in Human Liver Microsomes Using Feature-Based Molecular Networking. Pharmaceutics. 2026;18(6):731. doi:10.3390/pharmaceutics18060731

BibTeX
@article{Seo2026,
  author = {Seo, Hyung-Ju and Liang, Zhuoning and Kim, Eui-Hyeon and Liu, Kwang-Hyeon},
  title = {Characterization of Atrasentan Metabolic Pathway in Human Liver Microsomes Using Feature-Based Molecular Networking},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {731},
  doi = {10.3390/pharmaceutics18060731}
}
Kostenlos starten →